-

COPD Foundation Journal Receives High Ranking

WASHINGTON--(BUSINESS WIRE)--Last week, with receipt of its first impact factor, the peer-reviewed Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation (JCOPDF) became the highest-ranked COPD-focused journal among respiratory journals, according to Clarivate’s June 30, 2021, Journal Citation Report for 2020.

The highly anticipated 2020 impact factor is one journal quality and importance measure. The impact factor calculates how often articles published in the journal in 2018 and 2019 were cited in other published research articles in 2020.

“We are very pleased with our first impact factor,” said Mark Dransfield, MD, Editor in Chief of the JCOPDF. “Our journal is only seven years old, launched in 2014 by founding Editor in Chief James D. Crapo, MD, and the COPD Foundation’s founder, the late John W. Walsh. They envisioned an open access journal that could become the publishing home for important COPD-related research. And now their vision has been validated with this impact factor which categorizes the JCOPDF as the highest-ranked COPD-focused journal.”

Devoted to publishing original research, reviews, and perspectives on COPD—the fourth leading cause of death in the United States and the third leading cause of death worldwide—the JCOPDF has an editorial board of global COPD experts from 15 countries. It is published online quarterly with no barriers to access.

“For a non-profit foundation to publish a medical journal is no small feat, particularly in these times of large, multi-faceted, competing publishing conglomerates,” said Ruth Tal-Singer, PhD, President and Chief Scientific Officer of the COPD Foundation. “But encouraging and fostering innovative research and education is a critical part of the COPD Foundation’s mission. To receive this ranking—with our first impact factor—is both encouraging and reaffirming of our goals to understand COPD, bronchiectasis, and nontuberculous mycobacterial lung disease better, improve the lives of those who live with these devastating conditions, and ultimately find a cure.”

The COPD Foundation is a not-for-profit organization that was established to improve the lives of people with COPD, bronchiectasis, and nontuberculous mycobacterial (NTM) lung disease through initiatives that expand services and speed innovations which will make treatment more effective and affordable. We do this through scientific research, education, advocacy, and awareness with the goal of disease prevention, slowed progression, and ultimately a cure. Visit www.copdfoundation.org

Contacts

Carol Johnson, Communications Director
(786) 749-7104

COPD Foundation

Details
Headquarters: Miami, FL
CEO: Ruth Tal-Singer
Employees: 50+
Organization: NON

Release Summary
The Journal of the COPD Foundation became the highest-ranked COPD-focused journal among respiratory journals, in Clarivate’s Journal Citation Report.
Release Versions

Contacts

Carol Johnson, Communications Director
(786) 749-7104

More News From COPD Foundation

Seventy Percent (70%) of Patients Surveyed Voice Concern About Tobacco Corporations’ Ownership of Lung Disease Treatments

MIAMI--(BUSINESS WIRE)--Seventy percent (70%) of respondents to an international survey conducted earlier this year said they are either “bothered” or “really bothered” when tobacco companies make money from an inhaler, medication, or other devices that treat their lung conditions. The findings are available in a newly published communications brief, “Tobacco industry ownership of pharmaceutical companies: an international survey of people with respiratory disease,” in the Journal Thorax, the o...

Global Lung Health Organizations Partner for Inaugural World Bronchiectasis Day

WASHINGTON--(BUSINESS WIRE)--Global lung health organizations from the U.S, Europe, Australia, and Asia announce the formation of World Bronchiectasis Day on July 1, 2022....

COPD Foundation Condemns Big Tobacco Acquisition of Pharmaceutical Company

WASHINGTON--(BUSINESS WIRE)--COPD Foundation: A company profiting from the sale of products that cause COPD should not benefit from the sale of products that treat COPD....
Back to Newsroom